Zuranolone Launch Requires Sage To Shift The Way Doctors Treat Depression
US Approval Decision Expected By 5 August
Executive Summary
CEO Barry Greene and team spoke with Scrip about Sage and Biogen’s focus on short-term, episodic dosing, and said doctors and payers – pending zuranolone’s approval – are responding to the sales pitch.
You may also be interested in...
Aptinyx Pulls Back From Neuropsychiatry After Mid-Stage PD Failure
The US firm has faced yet another clinical setback as its Phase II candidate, NYX-458, failed to improve cognitive impairment in patients with Parkinson’s disease and Alzheimer’s, triggering the cessation of its only other program as priorities shift to preserving funds.
Axsome’s Wait Pays Off With Broad Auvelity Label For Major Depression
After a year-long delay, Axsome gets US FDA approval of bupropion/dextromethorphan combo with broad label for major depression. Firm expects to launch in Q4 with pricing intended for broad patient access.
Psychedelics Pipeline Overview: R&D Blossoms But No Panacea Among Candidates
While the psychedelic approach to mental health has recently achieved some clinical and regulatory validation, executives in the space warn the drugs cannot cure all and barriers to market remain.